Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$2.44 USD

2.44
1,622,130

-0.07 (-2.79%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $2.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

by Zacks Equity Research

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

by Zacks Equity Research

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Zacks Equity Research

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

by Zacks Equity Research

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

Zacks Equity Research

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

by Zacks Equity Research

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Zacks Equity Research

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sundeep Ganoria headshot

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

by Sundeep Ganoria

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

Zacks Equity Research

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.

Zacks Equity Research

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 92.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Illumina (ILMN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 200% and 1.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 5.56% and 39.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

by Zacks Equity Research

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

Zacks Equity Research

Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

by Zacks Equity Research

Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.

Zacks Equity Research

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of -20.63% and 90.26%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

by Zacks Equity Research

Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.

Zacks Equity Research

Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

by Zacks Equity Research

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

Zacks Equity Research

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 55.77% and 347.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of 157.69% and 119.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

Zacks Equity Research

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

by Zacks Equity Research

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

Zacks Equity Research

Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 80% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

by Zacks Equity Research

Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.